What The Study Did: This study of 1.1 million commercially insured patients with type 2 diabetes investigated whether there are inequities in use of a class of diabetes medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RA) based on race, ethnicity, sex and socioeconomic status.
Authors: Lauren A. Eberly, M.D., M.P.H., of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2021.4182)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2021.4182?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=121721
About JAMA Heath Forum: JAMA Health Forum has transitioned from an information channel to an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.
JAMA Health Forum